DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

2048
INDEX
Misuse, poisoning and, 80
Mitogen-activated protein kinase
inhibitors, 1056
Mitomycin, 1668t–1670t
for cancer, 1718–1719
Mitotane, 1236, 1668t–1670t
for cancer, 1719
Mitoxantrone, 1668t–1670t, 1715
ABC transporters and, 106t
pharmacokinetics of, 1865t
Mitral regurgitation, angina pectoris
with, recommended
treatment for, 769t
Mitral stenosis, angina pectoris with,
recommended treatment for,
769t
Mivacurium
characteristics of, 264t
dosing of, 265t
Mizolastine, 922t
MIZOLLEN (mizolastine), 922t
MK249, 925
MM. See Multiple myeloma (MM)
MOBIC (meloxicam), 990
Modafinil, pharmacokinetics of, 1866t
Moexipril, 733–734
as antihypertensive agent, 774t,
784–785
structure of, 732f
Molindone hydrochloride
dosage of, 424t
potencies at neurotransmitter
receptors, 427t
side effects of, 424t
Molluscum contagiosum, 1818
imiquimod for, 1823
Mometasone furoate
cream, 1225t
ointment, 1225t
Monascus purpureus, 893
Monitoring, therapeutic drug, 37–38
Monoamine oxidase inhibitors
(MAOIs), 404, 913
adrenergic receptors and, 207t
adverse effects of, 411
catecholamine transformation and,
200
drug interactions with, 412
manifestation of overdose
symptoms, 75t
mechanism of action, 408
for Parkinson, 618
pharmacokinetics, 408
Monoamine oxidase (MAO), 913
in catecholamine transformation, 200
Monoamine oxidase (MAO) inhibitors,
false-transmitter concept
and, 282
Monobenzone, 1830
MONOCID (cefonicid), 1494t
Monoclonal antibodies, 1016–1018
Monoclonal antibody(ies) (MAb),
1745–1750
antitumor activity, mechanism of
action of, 1731
chimeric, nomenclature for, 1745
cytotoxic conjugates, 1745,
1748–1750
dosing, 1747t
fully humanized, nomenclature for,
1745
for hematopoietic and solid tumors,
1746t
linked to toxin, 1745
radioimmunoconjugate, 1745, 1749
therapeutic, nomenclature for, 1745
toxicity of, 1747t
unarmed, 1745–1748
Monocyte/macrophage colonystimulating
factor (CSF-1;
M-CSF), 1070t
MONODOX (doxycycline), 1817
Monogenic trait, 152f
MONOPRIL (fosinopril), 733, 797
Montelukast, 942
pharmacokinetics of, 1866t
Mood alteration, with opioids, 493–
494
MOPEG. See 3-methyl, 4-hydroxy
phenylglycol (MOPEG)
8-MOP (methoxsalen), 1813
Morphine
absorption, distribution, fate, and
excretion of, 501
actions and selectivities of, 485t
ancient use of, 3
chemistry of, 499
dosage of, 500t
histamine and, 914
hypoglycemia and, 1248t
intraspinal infusion of, 500t
metabolism of, 128t, 502
pharmacokinetics of, 1866t
polymorphisms and response to,
159t
source and composition, 499
structure-activity relationship, 499
therapeutic actions and precautions,
502–503
and vasopressin secretion, 704
Motilides, 1327–1328
Motilin receptor agonists, 1328
Motion sickness
H 1
-receptor antagonists for, 920, 923
scopolamine for, 233
Motor end plate, 176
MOTRIN B (ibuprofen), 988
Mountain sickness, 681
Mouth, in sublingual
administration, 21
Moxifloxacin
for ophthalmic use, 1781t
pharmacokinetics of, 1867t
Mozavaptan, 714, 716t
adverse effects and side effects of,
714
pharmacokinetics of, 714
6-MP. See Mercaptopurine
MRFIT. See Multiple Risk Factor
Intervention Trial (MRFIT)
MRPs. See Multidrug resistanceassociated
proteins
MRTD. See Maximum Recommended
Therapeutic Dose
MT. See Methyltransferases (MT)
MTHFR. See
Methylenetetrahydrofolate
reductase (MTHFR)
MTOR inhibitors, 772, 1743–1745,
1744f
Mucolytics, 1057
Mucoregulators, 1056–1057
Mucormycosis, ocular, 1783
Mucosal toxicity, of alkylating agents,
1682
Mucous membranes, topical
application of drugs to, 23
MULTAQ (dronedarone), 839–840
Multi-chain triglycerides, 1346
Multicompartment volume
distribution, 31–32
Multidrug and toxin extrusion family
(MATEs), 112, 113
Multidrug resistance-associated protein
type 1 (MRP1), 104, 107
type 2 (MRP2), 93, 97, 100f, 103,
107, 115
type 3 (MRP3), 104, 107–108
type 4 (MRP4), 103–104, 106, 108,
115, 116
type 5 (MRP5), 106
type 6 (MRP6), 106
Multidrug resistance (MDR) gene,
1733
Multifetal gestation, 1843